What is Alzheimer's disease?
Alzheimer's disease is a mental illness. This is a common form of dementia. The disease slowly pushes man towards the brink of death. The disease was first discovered by the German psychiatrist and neuropathologist Alois Alzheimer in 1906, hence the name Alzheimer's.
Most often, Alzheimer's attacks people over the age of 65. Although the disease can occur before this age. In 2006, the disease affected 26.6 million people. According to one study, by 2050, one in eight people worldwide will be infected.
Causes
The cause of the disease has not yet been determined. Depression is one of the symptoms of this disease. There are four stages of this disease. The first is "pre-dementia", the second is "early", the third is "moderate" and the fourth and final is "extreme".
According to medical research, low blood sugar can lead to memory loss, which is a precursor to the disease. According to the study, published in Europe's leading medical journal Neuron, when blood sugar levels fall, the brain receives less glucose, which leads to a decrease in brain activity. Specific proteins trigger Alzheimer's disease.
Medical experts say that a successful attempt can be made to control the disease by keeping blood sugar levels normal. At the same time, it is important to control blood pressure, because high blood pressure can cause a disturbance in the ratio of glucose supply to the brain.
Treatment of Alzheimer's
The first human trial of the nasal vaccine is currently underway. It's been a long wait (20 years), but eventually, there's some hope for people with Alzheimer's disease.
The first experimental intranasal vaccine for the disease is currently being administered to humans in Boston, Massachusetts, and Brigham and Women's Hospital (BWH). The only medications available so far have helped control Alzheimer's symptoms such as memory loss or insomnia.
The vaccine, which will be given by nasal spray, uses an immune modulator, a protein made from bacteria and proteins, to stimulate the immune system. Through this, scientists hope that the white blood cells in the lymph nodes will be activated which will be transferred to the brain and will lead to the removal of beta-amyloid plaque. Deposits of beta-amyloid plaque that accumulate together. Which causes disease. It can completely slow down or stop the disease.
The purpose of the Phase 1 trial is to determine the safety and tolerability of the vaccine and to measure its effect on participants' immune response. The trial involved only 16 people between the ages of 60 and 85 with Alzheimer's symptoms.
In June this year, the Food and Drug Administration (FDA) approved the first new drug for Alzheimer's in almost 20 years, an antibody infusion called Aduhelm. This soon became controversial, however, when an FDA advisory committee questioned its usefulness and said that the evidence to improve its memory was conclusive.
In a statement, Dr. Howard Weiner, co-director of the Ann Romney Center for Neurological Diseases at BWH, called the study a "significant milestone."
He added: "If clinical trials in humans show that the vaccine is safe and effective, it could be an effective treatment for people with Alzheimer's, and Alzheimer's in people at risk. (Alzheimer's) can be given early to help prevent. "
According to the World Health Organization, about 55 million people are affected by the disease. "As the proportion of elderly people in the population continues to grow in almost every country, this number is expected to reach 78 million in 2030 and 139 million in 2050."
